Immutep Ltd
ASX:IMM

Watchlist Manager
Immutep Ltd Logo
Immutep Ltd
ASX:IMM
Watchlist
Price: 0.335 AUD -1.47% Market Closed
Market Cap: 487.3m AUD
Have any thoughts about
Immutep Ltd?
Write Note

Immutep Ltd
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Immutep Ltd
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Immutep Ltd
ASX:IMM
Selling, General & Administrative
-AU$8.9m
CAGR 3-Years
-12%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Mesoblast Ltd
ASX:MSB
Selling, General & Administrative
-$23.6m
CAGR 3-Years
9%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Selling, General & Administrative
-$2B
CAGR 3-Years
-8%
CAGR 5-Years
-7%
CAGR 10-Years
-10%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Selling, General & Administrative
-AU$36m
CAGR 3-Years
-23%
CAGR 5-Years
-32%
CAGR 10-Years
-21%
Telix Pharmaceuticals Ltd
ASX:TLX
Selling, General & Administrative
-AU$133.9m
CAGR 3-Years
-76%
CAGR 5-Years
-71%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Selling, General & Administrative
-AU$3.4m
CAGR 3-Years
22%
CAGR 5-Years
-8%
CAGR 10-Years
-5%
No Stocks Found

Immutep Ltd
Glance View

Market Cap
491.1m AUD
Industry
Biotechnology

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

IMM Intrinsic Value
0.728 AUD
Undervaluation 54%
Intrinsic Value
Price

See Also

What is Immutep Ltd's Selling, General & Administrative?
Selling, General & Administrative
-8.9m AUD

Based on the financial report for Jun 30, 2024, Immutep Ltd's Selling, General & Administrative amounts to -8.9m AUD.

What is Immutep Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-8%

Over the last year, the Selling, General & Administrative growth was -2%. The average annual Selling, General & Administrative growth rates for Immutep Ltd have been -12% over the past three years , -8% over the past five years , and -8% over the past ten years .

Back to Top